Patient adherence and persistence with oral anticancer treatment

CA Cancer Journal for Clinicians

Volumn 59, Issue 1, 2009, Pages 56-66

  Ruddy, Kathryn ^a,b   Mayer, Erica ^a   Partridge, Ann ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALTRETAMINE; ANASTROZOLE; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; EXEMESTANE; LETROZOLE; MERCAPTOPURINE; METHOTREXATE; PENICILLIN G; PREDNISOLONE; PREDNISONE; PROCARBAZINE; TAMOXIFEN; TOPOTECAN; UFT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BEHAVIOR THERAPY; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG HALF LIFE; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; INFORMATION TECHNOLOGY; LUNG SMALL CELL CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVARY CANCER; PATIENT COMPLIANCE; PATIENT EDUCATION; PEDIATRICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HEALTH BEHAVIOR; HUMANS; MEDICATION ADHERENCE; MOTIVATION; NEOPLASMS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC;

EID: 58849114208     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20004     Document Type: Review

References (78)

1. Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205-210.
2. Lonardi S, Bortolami A, Stefani M, et al. Oral anticancer drugs in the elderly: an overview. Drugs Aging. 2007;24:395-410.
3. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87:933-937.
4. Allen S. As oral cancer drugs gain, dosage problems grow. Boston Globe. February 4, 2007:Nation Section.
5. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-661.
6. Partridge AH, Ades T, Spicer P, et al. Helping breast cancer patients adhere to oral adjuvant hormonal therapy regimens. Community Oncol. 2007;4:725-731.
7. Urquhart J. Pharmionics: research on what patients do with prescription drugs. Pharmacoepidemiol Drug Saf. 2004;13:587-590.
8. Thompson AM, Dewar J, Fahey T, et al. Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer. Presented at the American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, California, 2007.
9. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
10. Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;34:407.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
12. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol. 1991;41:27-35.
13. Jasti S, Siega-Riz AM, Cogswell ME, et al. Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr. 2006;136:479-483.
14. Pullar T, Kumar S, Tindall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46:163-168.
15. Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther. 1989;46:169-176.
16. Steiner JF, Gardner EM. Assessing medication adherence from pharmacy records. Pharmacoepidemiol Drug Saf. 2006;15:575-577.
17. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7:5-9.
18. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
19. Haynes RB, Sackett DL, Taylor DW, et al. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin Pharmacol Ther. 1977;22:125-130.
20. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6:592-599.
21. Lebovits AH, Strain JJ, Schleifer SJ, et al. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17-22.
22. Blackwell B, Bloomfield SS, Buncher CR. Demonstration to medical students of placebo responses and non-drug factors. Lancet. 1972;1:1279-1282.
23. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71:3441-3449.
24. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10-15.
25. Urquhart J. Compliance and clinical trials. Lancet. 1991;337:1224-1225.
26. Soran A, Nesbitt L, Mamounas EP, et al. Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience. Clin Trials. 2006;3:478-485.
27. Partridge AH, Archer LE, Kornblith AB, et al. CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. Presented at the 2008 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, Dates, 2008.
28. Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm. 2007;13:S2-S12; quiz S13-S14.
29. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
30. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-2442.
31. Dezii CM. Medication noncompliance: what is the problem? Manag Care. 2000;9:7-12.
32. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17:565-576.
33. Haynes RB. A critical review of the "determinants" of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RB, eds. Compliance with Therapeutic Regimens. Baltimore: The Johns Hopkins University Press; 1976:26-39.
34. Smith A, Mucklow JC, Wandless I. Compliance with drug treatment. BMJ. 1979;1:1335-1336.
35. Tebbi CK, Cummings KM, Zevon MA, et al. Compliance of pediatric and adolescent cancer patients. Cancer. 1986;58:1179-1184.
36. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997;76:365-366.
37. Sabate E. Adherence to long-term therapies, evidence for action. World Health Organization 2003. Available at: http://whqlibdoc.who.int/publications/ 2003/9241545992.pdf. pp 1-169.
38. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
39. Wong BS, Norman DC. Evaluation of a novel medication aid, the calendar blister-pak, and its effect on drug compliance in a geriatric outpatient clinic. J Am Geriatr Soc. 1987;35:21-26.
40. Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther. 1994;32:452-457.
41. Becker MH, Maiman LA, Kirscht JP, et al. The Health Belief Model and prediction of dietary compliance: a field experiment. J Health Soc Behav. 1977;18:348-366.
42. Lansky SB, Smith SD, Cairns NU, et al. Psychological correlates of compliance. Am J Pediatr Hematol Oncol. 1983;5:87-92.
43. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? Br J Cancer. 1995;72:1004-1006.
44. Tamaroff MH, Festa RS, Adesman AR, et al. Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates. J Pediatr. 1992;120:812-817.
45. Smith SD, Rosen D, Trueworthy RC, et al. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979;43:169-173.
46. Festa RS, Tamaroff MH, Chasalow F, et al. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr. 1992;120:807-811.
47. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880-2883.
48. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189-1197.
49. Veronesi A, Pizzichetta MA, Ferlante MA, et al. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori. 1998;84:372-375.
50. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469-1476.
51. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol. 1988;6:1746-1752.
52. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol. 1992;10:1007-1013.
53. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer. 1993;67:630-634.
54. Lee CR, Nicholson PW, Ledermann JA, et al. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol. 1996;17:99-103.
55. Sadahiro S, Ohki S, Yamaguchi S, et al. Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol. 2000;46:180-184.
56. Murthy V, Bharia G, Sarin R. Tamoxifen non-compliance: does it matter? Lancet Oncol. 2002;3:654.
57. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602-606.
58. Grunfeld EA, Hunter MS, Sikka P, et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97-102.
59. Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodys-plastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006;57:199-206.
60. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271-2276.
61. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109:832-839.
62. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556-562.
63. Escalada P, Griffiths P. Do people with cancer comply with oral chemotherapy treatments? Br J Community Nurs. 2006;11:532-536.
64. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322-328.
65. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309-3315.
66. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the 5-year course. Breast Cancer Res Treat. 2006;99:215-220.
67. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
68. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
69. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
70. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71:1-9.
71. Leventhal H, Nerenz DR, Leventhal EA, et al. The behavioral dynamics of clinical trials. Prev Med. 1991;20:132-146.
72. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549-555.
73. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-2879.
74. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005;(4);CD000011.
75. Macintosh PW, Pond GR, Pond BJ, et al. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl). 2007;16:380-386.
76. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(3):CD000336.
77. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571.
78. Malbasa T, Kodish E, Santacroce SJ. Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs. 2007;24:139-151.